{"id":190262,"date":"2018-02-23T12:07:11","date_gmt":"2018-02-23T12:07:11","guid":{"rendered":"http:\/\/www.abnewswire.com\/pressreleases\/?p=190262"},"modified":"2018-02-23T12:07:11","modified_gmt":"2018-02-23T12:07:11","slug":"newly-published-by-visiongain-global-parkinsons-disease-drug-market-forecast-20182028-report","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/newly-published-by-visiongain-global-parkinsons-disease-drug-market-forecast-20182028-report_190262.html","title":{"rendered":"Newly published by Visiongain: Global Parkinson\u2019s Disease Drug Market Forecast 2018-2028 report"},"content":{"rendered":"<div style=\" width:250px; padding:8px 10px 10px 10px; float:right;\"><a href=\"http:\/\/www.abnewswire.com\/pressreleases\/wp-content\/uploads\/2018\/02\/1519385486.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"image\" src=\"http:\/\/www.abnewswire.com\/pressreleases\/wp-content\/uploads\/2018\/02\/1519385486.png\" alt=\"\" width=\"225\" height=\"131\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\" style=\" font-weight:bold; font-style:italic;\">\n<div>&#8220;Africa Parkinsons Disease Drug Industry and Forecast&#8221;<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">This report covers the Global Parkinson&#8217;s Disease Drug Market Forecast 2018-2028, including the following: Carbidopa, Dopamine Receptor Antagonists, MAO-Inhibitors, COMT-Inhibitors, Anticholinergics, Distribution Channels and End-Users<\/div>\n<p style=\"text-align: justify;\"><strong>Our new study reveals trends, R&amp;D progress, and predicted revenues<\/strong><\/p>\n<p style=\"text-align: justify;\">Our new report discusses issues and events affecting the Parkinson&rsquo;s disease therapeutics market. Our new report provides qualitative analyses to answer these key questions:<br \/> &bull; How is the Parkinson&rsquo;s disease therapeutics market evolving?<br \/> &bull; What is driving and restraining the Parkinson&rsquo;s disease therapeutics market?<br \/> &bull; How will political and regulatory factors influence the regional markets and submarkets?<br \/> &bull; Who are the leading Parkinson&rsquo;s disease therapeutics companies, and what are their prospects over the forecast period?<br \/> &bull; What are the predictions for M&amp;A activity, consolidation for existing players and the potential prospects for new market entrants?<\/p>\n<p style=\"text-align: justify;\"><strong>Forecasts from 2018-2028 and other analyses show you commercial prospects<\/strong><br \/> Our new report provides quantitative analyses to answer these key questions:<br \/> &bull; What are the market shares of the Parkinson&rsquo;s therapeutics disease market in 2017?<br \/> &bull; How will each of the drugs in the Parkinson&rsquo;s therapeutics market grow over the forecast period and how much revenue will these drugs account for in 2028?<br \/> &bull; What Parkinson&rsquo;s disease drugs are in the development pipeline?<br \/> &bull; How will each of Parkinson&rsquo;s disease diagnostics market grow over the forecast period and how much revenue will these submarkets account for in 2028?<br \/> &bull; How will the market shares of the national markets change by 2028 and which geographical region will lead the market in 2028?<\/p>\n<p style=\"text-align: justify;\">Besides revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares. We provide original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT and STEP), company profiles and commercial developments.<\/p>\n<p style=\"text-align: justify;\">Many opportunities exist for the treatment of Parkinson&rsquo;s. Our new study shows you the most promising and lucrative parts of that CNS market, helping you stay ahead.<\/p>\n<p style=\"text-align: justify;\"><strong>Discover sales predictions for the world market and submarkets<\/strong><br \/> Discover in our report overall world revenue to 2028 for Parkinson&rsquo;s disease medicines. Also explore individual revenue predictions to 2028 for six therapeutic submarkets at world level:<\/p>\n<p style=\"text-align: justify;\"><strong>&bull; Levodopa\/ Carbidopa<br \/> &bull; Dopamine Receptor Agonists<br \/> &bull; MAO-inhibitors<br \/> &bull; COMT-inhibitors<br \/> &bull; Anticholinergics<br \/> &bull; Other Therapeutic Options<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Each submarket is further broken down by region:&nbsp;<\/strong>North America, South America, Europe, Asia-Pacific and ROW.<\/p>\n<p style=\"text-align: justify;\">Our investigation discusses what stimulates and restrains business. You find dynamics of the industry and assess its potential sales, seeing agents likely to achieve the most success.<\/p>\n<p style=\"text-align: justify;\">This report also breaks down the revenue forecast for the Global Parkinson&rsquo;s Disease drugs market&nbsp;<strong>by Distribution Channel:<br \/> &bull; Hospital Pharmacies<br \/> &bull; Retailer Pharmacies<br \/> &bull; Online Pharmacies<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Each submarket is further broken down by region:<\/strong>&nbsp;North America, South America, Europe, Asia-Pacific and ROW.<\/p>\n<p style=\"text-align: justify;\">This report also breaks down the revenue forecast for the Global Parkinson&rsquo;s Disease drugs market&nbsp;<strong>by End-User:<br \/> &bull; Hospitals<br \/> &bull; Clinics<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Each submarket is further broken down by region:&nbsp;<\/strong>North America, South America, Europe, Asia-Pacific and ROW.<\/p>\n<p style=\"text-align: justify;\"><strong>What are the prospects in the leading regions and countries?<\/strong><br \/> Developments worldwide expand the market for diagnosing, treating and monitoring neurodegenerative disorders. Developed and developing national markets hold high potential from 2017.<\/p>\n<p style=\"text-align: justify;\">Our work also shows individual revenue forecasts to 2028 for 20 national markets:<br \/> <strong>&bull; North America&nbsp;<\/strong>&ndash; US, Canada, Mexico<br \/> <strong>&bull; South America<\/strong>&nbsp;&ndash; Brazil, Argentina, Paraguay, Bolivia<br \/> <strong>&bull; Europe<\/strong>&nbsp;&ndash; Germany, France, UK, Italy, Spain and Russia<br \/> <strong>&bull; Asia Pacific&nbsp;<\/strong>&ndash; China, Japan, India, Australia, Thailand<br \/> <strong>&bull; ROW&nbsp;<\/strong>&ndash; Middle East, Africa<\/p>\n<p style=\"text-align: justify;\"><strong>Leading companies and potential for market growth<\/strong><br \/> In 2017 the overall Global Parkinson&rsquo;s Disease drug market generated $4.10bn. Visiongain predicts its revenues in 2022 to reach $5.70bn. Our work shows you what organisation hold greatest potential. See profiles of leading companies in this sector:<br \/> &bull; Astrazeneca<br \/> &bull; Merck &amp;Co.<br \/> &bull; Novartis AG<br \/> &bull; GlaxoSmith Kline<br \/> &bull; Roche<br \/> &bull; Pfizer<br \/> &bull; Abbvie<br \/> &bull; Biogen Inc.<br \/> &bull; Acorda Therapeutics Inc<\/p>\n<p style=\"text-align: justify;\"><strong>What affects producers of those medicines?<\/strong><br \/> Our report discusses issues and events affecting that industry and market from 2017, including these:<br \/> &bull; Research and development (R&amp;D) &ndash; drugs, diagnostic tests, and related technologies<br \/> &bull; Disease prevalence &ndash; expanding patient populations<br \/> &bull; Disease-modifying drugs and obstacles to cures<br \/> &bull; Regulatory guidelines &ndash; changes and opportunities.<br \/> &bull; Drugs and related technologies to transform the market<br \/> &bull; Biomarkers<br \/> &bull; Deep brain stimulation (functional neuromodulation)<br \/> &bull; Intellectual property (IP), licensing agreements and partnerships.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Please email sara.peerun@visiongain.com for a free report overview or call her on +44 207 549 9987<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Our 152-page report provides 82 Tables and 85 Figures.<\/strong>&nbsp;Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and national level. You will see financial results, interviews trends and opportunities, and revenue predictions.<\/p>\n<p style=\"text-align: justify;\">Benefit your work now through our updated study, gaining original industry and market analysis:<br \/> <strong>&bull; Revenues for Parkinson&rsquo;s disease treatments to 2028<\/strong>&nbsp;&ndash; assess that overall world drugs market&rsquo;s potential and get forecasted revenues for the six leading sub-classes: Levodopa\/Carbidopa, Dopamine receptor agonists, COMT- and MAO-inhibitors, Anticholinergics, and other therapeutic options.<br \/> <strong>&bull; National market forecasting to 2028 for 20 countries in the Americas, Europe, Asia, Middle East and Africa<\/strong>&nbsp;&ndash; explore the best regions for treatment demand, sales and growth<br \/> <strong>&bull; R&amp;D activities&nbsp;<\/strong>&ndash; see progress, trends and prospects in research and development, finding technological, clinical and commercial possibilities<br \/> <strong>&bull; Analysis of what stimulates and restrains that industry and market<\/strong>&nbsp;&ndash; assess challenges and strengths there, helping you compete and gain advantages.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Please email sara.peerun@visiongain.com for a free report overview or call her on +44 207 549 9987<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Companies listed in this report include:<\/p>\n<p style=\"text-align: justify;\">Abbvie<br \/> Acorda Therapeutics Inc.<br \/> AstraZeneca<br \/> BioArtic<br \/> Biogen Inc.<br \/> Biotie Therapies<br \/> Center for Disease Control and Prevention (CDC)<br \/> Civitas Therapeutics<br \/> Food and Drugs Administration (FDA)<br \/> GlaxoSmithKline<br \/> Health Canada<br \/> IBM<br \/> Merck &amp; Co.<br \/> Novartis<br \/> Parkinson&rsquo;s Association<br \/> Parkinson&rsquo;s Institute and Clinical Centre<br \/> Pfizer<br \/> Pharmaceuticals and Medical Devices Agency (PMDA)<br \/> Prothena<br \/> Roche<br \/> Servizio Sanitario Nazionale (SSN)<br \/> Takeda<br \/> UCB S.A<br \/> World Health Organisation (WHO)<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> Visiongain Limited<br \/><strong>Contact Person:<\/strong> Sara Peerun<br \/><strong>Email:<\/strong> sara.peerun@visiongain.com<br \/><strong>Phone:<\/strong> +44 207 3366100<br \/><strong>Address:<\/strong>143 Airport House, Purley way  <br \/><strong>City:<\/strong> London CR0 0XZ<br \/><strong>Country:<\/strong> United Kingdom<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.visiongain.com\/Report\/2105\/Global-Parkinson%E2%80%99s-Disease-Drug-Market-Forecast-2018-2028\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.visiongain.com\/Report\/2105\/Global-Parkinson%E2%80%99s-Disease-Drug-Market-Forecast-2018-2028<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.visiongain.com\/Report\/2105\/Global-Parkinson%E2%80%99s-Disease-Drug-Market-Forecast-2018-2028\" style=\"width:605px; height:400px;\"><\/object><\/p>\n<p><img decoding=\"async\" src=\"http:\/\/www.abnewswire.com\/press_stat.php?pr=newly-published-by-visiongain-global-parkinsons-disease-drug-market-forecast-20182028-report\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>&#8220;Africa Parkinsons Disease Drug Industry and Forecast&#8221; This report covers the Global Parkinson&#8217;s Disease Drug Market Forecast 2018-2028, including the following: Carbidopa, Dopamine Receptor Antagonists, MAO-Inhibitors, COMT-Inhibitors, Anticholinergics, Distribution Channels and End-Users Our new study reveals trends, R&amp;D progress, and &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/newly-published-by-visiongain-global-parkinsons-disease-drug-market-forecast-20182028-report_190262.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401],"tags":[],"class_list":["post-190262","post","type-post","status-publish","format-standard","hentry","category-Business"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/190262","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=190262"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/190262\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=190262"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=190262"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=190262"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}